Literature DB >> 19604238

Altered mRNA expression of PAX5 is a common event in acute lymphoblastic leukaemia.

Alessandra Santoro, Maria G Bica, Lea Dagnino, Cecilia Agueli, Domenico Salemi, Sonia Cannella, Marinella Veltroni, Valentina Cetica, Emanuela Giarin, Francesco Fabbiano, Giuseppe Basso, Maurizio Arico.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19604238     DOI: 10.1111/j.1365-2141.2009.07815.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

1.  The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party.

Authors:  Ilaria Iacobucci; Annalisa Lonetti; Francesca Paoloni; Cristina Papayannidis; Anna Ferrari; Clelia Tiziana Storlazzi; Marco Vignetti; Daniela Cilloni; Francesca Messa; Viviana Guadagnuolo; Stefania Paolini; Loredana Elia; Monica Messina; Antonella Vitale; Giovanna Meloni; Simona Soverini; Fabrizio Pane; Michele Baccarani; Robin Foà; Giovanni Martinelli
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

2.  Signaling proteins and transcription factors in normal and malignant early B cell development.

Authors:  Patricia Pérez-Vera; Adriana Reyes-León; Ezequiel M Fuentes-Pananá
Journal:  Bone Marrow Res       Date:  2011-05-20

3.  Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations.

Authors:  Matthew R Hart; Donovan J Anderson; Christopher C Porter; Tobias Neff; Michael Levin; Marshall S Horwitz
Journal:  PLoS Genet       Date:  2018-09-14       Impact factor: 5.917

4.  Risk assessment of FLT3 and PAX5 variants in B-acute lymphoblastic leukemia: a case-control study in a Pakistani cohort.

Authors:  Ammara Khalid; Sara Aslam; Mehboob Ahmed; Shahida Hasnain; Aimen Aslam
Journal:  PeerJ       Date:  2019-09-10       Impact factor: 2.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.